Back to top
more

Altimmune (ALT)

(Delayed Data from NSDQ)

$7.26 USD

7.26
2,250,676

+0.06 (0.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.25 -0.01 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?

by Zacks Equity Research

Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.

    HCA Healthcare (HCA) Scraps Utah Buyout Post FTC's Roadblock

    by Zacks Equity Research

    HCA Healthcare's (HCA) aborted acquisition follows another abandoned buyout plan involving RWJBarnabas Health and Saint Peter's Healthcare System.

    Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund

    by Zacks Equity Research

    Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.

    Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

    Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet

    by Zacks Equity Research

    The mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

    Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?

    by Zacks Equity Research

    The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

    Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Altimmune, Inc. (ALT) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Altimmune, Inc. (ALT) delivered earnings and revenue surprises of -125.00% and 49.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    by Zacks Equity Research

    Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

    Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know

    by Zacks Equity Research

    Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More

    by Zacks Equity Research

    The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.

    Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

    by Zacks Equity Research

    Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

    Do Options Traders Know Something About Altimmune (ALT) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

    Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Altimmune, Inc. (ALT) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

    by Zacks Equity Research

    Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

    Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine

    by Zacks Equity Research

    Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.

    Company News for Jul 13, 2020

    by Zacks Equity Research

    Companies in the news are: BNGO, AMRX, ALT, EXPR